Burlington, VTNCT05683808Now EnrollingIRB Ready

Glioblastoma Clinical Trial in Burlington, VT

Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Burlington. Study-provided care at no cost to qualified participants.

Sponsored by University of Vermont Medical Center

Quick Self-Assessment

See if you qualify for this Burlington location

Preparing your pre-screening questions…

Expert Care in Burlington

Access glioblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma treatment provided free

Apply for This Burlington Location

Check if you qualify for this glioblastoma clinical trial in Burlington, VT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Burlington

    Convenient for VT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Burlington site if eligible
  4. 4Begin participation

About This Glioblastoma Study in Burlington

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

Sponsor: University of Vermont Medical Center

Who Can Participate

Inclusion Criteria

Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
Age 18 and old
Karnofsky performance status (KPS) 60-100
Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
Ability to provide informed consent.
Planning for treatment with radiation and chemotherapy.

Exclusion Criteria

Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.
Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.
Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
Estimated life expectancy of \<3 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Burlington?

Yes, this clinical trial (NCT05683808) has an active research site in Burlington, VT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Treatment Options in Burlington, VT

If you're searching for glioblastoma treatment options in Burlington, VT, this clinical trial (NCT05683808) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Burlington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Burlington, VT

See all brain cancer clinical trials recruiting in Burlington — not just this study.

Browse Brain Cancer Trials in Burlington →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Burlington?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Burlington, VT